Alterity Therapeutics (ATHE) News Today $5.14 -0.16 (-3.02%) Closing price 03:59 PM EasternExtended Trading$5.29 +0.15 (+2.90%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Appendix 4C – Q4 FY25 Quarterly Cash Flow ReportJuly 30, 2025 | globenewswire.comAlterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System AtrophyJuly 28, 2025 | globenewswire.comAlterity Therapeutics Ltd. ADR (ATHE) Stock Price Today - WSJJuly 26, 2025 | wsj.comAlterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History StudyJuly 24, 2025 | globenewswire.comAlterity Therapeutics to Provide Corporate Update in Fireside ChatJune 23, 2025 | globenewswire.comAlterity Therapeutics highlighted at MSA CongressMay 14, 2025 | uk.investing.comAlterity Therapeutics Prominently Featured at the International MSA CongressMay 12, 2025 | globenewswire.comAlterity Therapeutics Secures FDA Fast Track Designation For ATH434 For MSA TreatmentMay 7, 2025 | nasdaq.comAlterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA CongressMay 7, 2025 | globenewswire.comALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System AtrophyMay 5, 2025 | finanznachrichten.deAlterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System AtrophyMay 5, 2025 | globenewswire.comAppendix 4C – Q3 FY25 Quarterly Cash Flow ReportApril 30, 2025 | globenewswire.comAlterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA SymposiumApril 28, 2025 | globenewswire.comAlterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual MeetingApril 10, 2025 | globenewswire.comAlterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual MeetingApril 10, 2025 | globenewswire.comALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System AtrophyMarch 28, 2025 | finanznachrichten.deAlterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System AtrophyMarch 27, 2025 | globenewswire.comAlterity Therapeutics Raises A$40.0 million in PlacementFebruary 10, 2025 | globenewswire.comAlterity Therapeutics to raise $40 million, MST Financial on ticketFebruary 5, 2025 | afr.comAlterity Therapeutics downgraded to Hold from Speculative Buy at BenchmarkFebruary 3, 2025 | markets.businessinsider.comAlterity Vaults on Drug Test ResultsJanuary 30, 2025 | baystreet.caAlterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical EfficacyJanuary 30, 2025 | globenewswire.comAlterity Therapeutics announces trading haltJanuary 28, 2025 | msn.comAppendix 4C – Q2 FY25 Quarterly Cash Flow ReportJanuary 24, 2025 | globenewswire.comALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesJanuary 9, 2025 | finanznachrichten.deAlterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesJanuary 9, 2025 | globenewswire.comAlterity Therapeutics Limited (PRNAF)December 20, 2024 | nz.finance.yahoo.comMaxim Group Initiates Coverage of Alterity Therapeutics Limited - Depositary Receipt () (ATHE) with Buy RecommendationDecember 13, 2024 | msn.comAlterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System AtrophyDecember 4, 2024 | globenewswire.comAlterity Therapeutics announces change in company secretaryNovember 21, 2024 | investing.comAlterity Therapeutics Appoints Abby Macnish Niven as Company SecretaryNovember 19, 2024 | globenewswire.comAlterity Therapeutics announces presentation on bioMUSE studyNovember 13, 2024 | markets.businessinsider.comAlterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International SymposiumNovember 12, 2024 | globenewswire.comAlterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434November 6, 2024 | globenewswire.comAlterity Therapeutics reports cash balance of A$9.28M as of September 30October 31, 2024 | markets.businessinsider.comAppendix 4C – Q1 FY25 Quarterly Cash Flow ReportOctober 31, 2024 | globenewswire.comAlterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024October 14, 2024 | globenewswire.comAlterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience MeetingOctober 11, 2024 | globenewswire.comAlterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®October 2, 2024 | globenewswire.comALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial OfficerSeptember 30, 2024 | finanznachrichten.deMarsh McLennan strikes $7.75 billion deal for McGriff Insurance ServicesSeptember 30, 2024 | ca.finance.yahoo.comAlterity Therapeutics Appoints Abby Macnish Niven as Chief Financial OfficerSeptember 30, 2024 | finance.yahoo.comAlterity Therapeutics Appoints Abby Macnish Niven as Chief Financial OfficerSeptember 30, 2024 | globenewswire.comAlterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®September 23, 2024 | globenewswire.comAlterity Therapeutics Ltd (ATH)August 30, 2024 | investing.comAlterity Therapeutics Ltd (PBN.SG)August 17, 2024 | nz.finance.yahoo.comAlterity Therapeutics Ltd (PBN.HM)August 5, 2024 | finance.yahoo.comAppendix 4C – Q4 FY24 Quarterly Cash Flow ReportJuly 31, 2024 | globenewswire.comAlterity Therapeutics to Present at MST Financial WebinarJuly 24, 2024 | globenewswire.comAlterity Therapeutics: ATH434-202 Phase 2 Clinical Trial Shows Positive Data In MSAJuly 19, 2024 | markets.businessinsider.com Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address ATHE Media Mentions By Week ATHE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATHE News Sentiment▼1.870.71▲Average Medical News Sentiment ATHE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATHE Articles This Week▼10▲ATHE Articles Average Week Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DMAC News Today CRDF News Today RAPT News Today LYEL News Today ACRS News Today SLS News Today CLLS News Today VYGR News Today DERM News Today CTOR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATHE) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access